Can one infusion replace a lifetime of cholesterol pills?
In this phase 1, open-label, single-ascending-dose trial in 35 adults, one intravenous infusion of the base-editing therapy VERVE-102 lowered LDL (“bad”) cholesterol by 62 percent at the highest dose, with no dose-limiting toxic effects. That is an absolute drop of 78 mg/dL from a single treatment, and the reductions appeared durable throughout follow-up, which was at least 1 year in 15 participants.
For people with inherited high cholesterol, this is a striking early result. Most patients with this condition take medicines every day, and many still cannot get their numbers into a safe range. A one-time infusion designed to durably turn down the body’s cholesterol-raising gene is a different approach to the problem.
How the treatment works
The liver makes a protein called PCSK9, and people who carry loss-of-function variants of the PCSK9 gene have lower LDL cholesterol and fewer atherosclerotic cardiovascular disease events than people without those variants. That natural experiment is what inspired this treatment.
VERVE-102 is an in vivo base-editing therapy designed to durably inactivate PCSK9 in the liver. The infusion contains a messenger RNA encoding an adenine base-editor protein along with a guide RNA that targets PCSK9, both encapsulated in a lipid nanoparticle incorporating N-acetylgalactosamine. Rather than being taken daily, it is given once, and the intent is a lasting change in how much PCSK9 the liver makes.
What the data show
The trial enrolled adults who had either heterozygous familial hypercholesterolemia or premature coronary artery disease. Each participant received one intravenous infusion at one of six doses, ranging from 0.3 to 1.0 mg of total RNA per kilogram of body weight. A total of 35 participants across the six dose cohorts received VERVE-102 and had at least 28 days of follow-up.
The effect tracked the dose. Mean reductions in blood PCSK9 ranged from 51 percent at the 0.3-mg-per-kilogram dose to 88 percent at the 1.0-mg-per-kilogram dose. LDL cholesterol followed the same pattern, with mean reductions from 9 percent at the lowest dose to 62 percent at the highest, an absolute reduction of 78 mg/dL at that top dose. The reductions appeared to be durable throughout follow-up, which reached at least 1 year in 15 participants.
Dr. Kumar’s Take
I find this study genuinely encouraging, and I want to be careful about why. Human genetics already showed that lower lifetime PCSK9 tracks with lower LDL and fewer cardiovascular events. What is new here is doing it with a single infusion rather than a daily or repeated dose, and seeing the LDL reduction hold across the follow-up reported so far. For my patients with familial hypercholesterolemia, who carry a high LDL burden from birth despite doing everything right, that idea is a big deal.
That said, this is a small phase 1, open-label trial. The longest follow-up reported is at least 1 year in a minority of participants, so I cannot say what happens over decades. There is also no outcome data here on heart attacks or strokes. I am optimistic, and I still want larger trials and longer follow-up before I would recommend this outside a research setting.
Who this could help most
The people who stand to gain most are those whose biology works against them. Heterozygous familial hypercholesterolemia causes lifelong high LDL that daily medicines often cannot fully control, and this trial deliberately enrolled that group along with people who already have premature coronary artery disease.
The practical appeal is simplicity. Today, managing this kind of LDL means daily medicine, regular blood tests, and dose adjustments over a lifetime. A durable, single-dose option could change that pattern, and it could help people who have difficulty taking medicine consistently for any reason.
Safety, limits, and caveats
No dose-limiting toxic effects occurred, which is reassuring at this stage. The trial did report mild-to-moderate infusion-related reactions and transient elevations in alanine aminotransferase levels, a liver enzyme, which fits a therapy delivered to the liver. Aspiration pneumonitis occurred in one participant who had gastroesophageal reflux disease. None of that is trivial, and all of it needs to be tracked in larger studies.
Two questions still need real answers. First, does the LDL reduction translate into fewer cardiovascular events? The genetic evidence in people with PCSK9 loss-of-function variants points that way, but this trial measured blood levels, not outcomes. Second, what happens over a lifetime after a durable edit to liver DNA? The 35 participants studied here, followed for at least 28 days and in 15 cases at least 1 year, cannot answer that. Until they do, this is a powerful proof of concept, not a routine treatment.
Practical Takeaways
- Keep taking your current cholesterol medicines as prescribed, because this therapy has not yet demonstrated reduced heart attacks or strokes and remains investigational.
- If your LDL stays high despite treatment, talk with your doctor about intensifying your current regimen rather than waiting for something that is still in phase 1 testing.
- Get a lipid panel regularly if you have a family history of early heart disease, since high LDL identified early gives you far more time to protect your arteries.
Related Studies and Research
For more context on cholesterol, statins, and heart disease prevention, these articles are worth a read:
- Does high LDL-C help elderly people live longer? A review of 19 studies
- Does rosuvastatin prevent heart disease in healthy people with intermediate risk? A look at the HOPE-3 trial
- Time-restricted feeding cuts Crohn’s disease activity in new trial
- High-dose intravenous vitamin C boosts chemo sensitivity in ovarian cancer
FAQs
How long does the effect of VERVE-102 last?
VERVE-102 is designed to durably inactivate PCSK9 in the liver after a single infusion. In this trial the reductions in PCSK9 and LDL cholesterol appeared durable throughout follow-up, which was at least 1 year in 15 participants. That is the full extent of what has been reported so far, which is why long-term safety follow-up matters so much here.
What is actually in a dose of VERVE-102?
The infusion carries two pieces of genetic material: a messenger RNA that encodes an adenine base-editor protein, and a guide RNA that directs that editor to PCSK9. Both are encapsulated in a lipid nanoparticle that incorporates N-acetylgalactosamine. In this trial the total RNA dose ranged from 0.3 to 1.0 mg per kilogram of body weight across six cohorts, and the effect on both PCSK9 and LDL rose with the dose.
Why focus on PCSK9 instead of lowering LDL another way?
PCSK9 is a natural experiment built into human biology. People who carry loss-of-function variants of the PCSK9 gene have reduced LDL cholesterol levels and fewer atherosclerotic cardiovascular disease events than people without such variants. Building a therapy that inactivates PCSK9 copies a pattern that human genetics has already demonstrated, which is why this target has drawn so much attention.
Bottom Line
A single intravenous infusion of VERVE-102 reduced LDL cholesterol by 62 percent and PCSK9 by 88 percent at the highest of six doses tested in 35 adults, an absolute LDL drop of 78 mg/dL, with no dose-limiting toxic effects and reductions that appeared durable throughout follow-up, which was at least 1 year in 15 participants. This is proof of concept that a one-time base edit can produce substantial, sustained LDL lowering in humans. The next step is larger and longer trials showing whether that translates into fewer cardiovascular events.
